The estimated Net Worth of Keith Regnante is at least 2.77 百万$ dollars as of 4 November 2023. Mr Regnante owns over 40,000 units of Keros Therapeutics stock worth over 2,190,000$ and over the last 8 years he sold KROS stock worth over 64,203$. In addition, he makes 518,569$ as Chief Financial Officer at Keros Therapeutics.
Mr has made over 5 trades of the Keros Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 40,000 units of KROS stock worth 640,000$ on 4 November 2023.
The largest trade he's ever made was exercising 40,000 units of Keros Therapeutics stock on 4 November 2023 worth over 640,000$. On average, Mr trades about 7,937 units every 149 days since 2016. As of 4 November 2023 he still owns at least 40,000 units of Keros Therapeutics stock.
You can see the complete history of Mr Regnante stock trades at the bottom of the page.
Keith C. Regnante is the Chief Financial Officer at Keros Therapeutics.
As the Chief Financial Officer of Keros Therapeutics, the total compensation of Mr Regnante at Keros Therapeutics is 518,569$. There are 2 executives at Keros Therapeutics getting paid more, with Dr. Jasbir Seehra Ph.D. having the highest compensation of 908,087$.
Mr Regnante is 51, he's been the Chief Financial Officer of Keros Therapeutics since . There are 1 older and 2 younger executives at Keros Therapeutics. The oldest executive at Keros Therapeutics, Inc. is Dr. Jasbir Seehra Ph.D., 65, who is the Pres, CEO, Treasurer, & Director.
Keith's mailing address filed with the SEC is C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421.
Over the last 5 years, insiders at Keros Therapeutics have traded over 50,765,607$ worth of Keros Therapeutics stock and bought 2,504,088 units worth 46,191,339$ . The most active insiders traders include Ran Nussbaum、Carl L Gordon、Tomer Kariv. On average, Keros Therapeutics executives and independent directors trade stock every 25 days with the average trade being worth of 3,312,649$. The most recent stock trade was executed by Carl L Gordon on 13 August 2024, trading 250,000 units of KROS stock currently worth 11,002,500$.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Keros Therapeutics executives and other stock owners filed with the SEC include: